Chandan Healthcare (NSE:CHANDAN) Research & Development: ₹0 Mil (TTM As of Dec. 2025)


NSE:CHANDAN Chandan Healthcare Ltd NSE:CHANDAN
28 GF Score
Price ₹253.00
! 4 Warning Signs
View Full Analysis

What is Chandan Healthcare Research & Development?

Chandan Healthcare NSE:CHANDAN +1.20% 28 Research & Development is ₹0 Mil as of Dec. 2025. GuruFocus rates NSE:CHANDAN with a GF Score™ of 28/100. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Chandan Healthcare's Research & Development for the three months ended in Dec. 2025 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was ₹0 Mil.

Chandan Healthcare  (NSE:CHANDAN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Chandan Healthcare Research & Development Related Terms

Chandan Healthcare Research & Development Historical Data

* Premium members only.

The historical data trend for Chandan Healthcare's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chandan Healthcare Research & Development Chart

Chandan Healthcare Annual Data
Trend Mar22 Mar23 Mar24 Mar25
Research & Development
0.00 0.00 0.00 0.00

Chandan Healthcare Quarterly Data
Mar22 Mar23 Mar24 Dec24 Mar25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
NSE:CHANDAN
28GF Score
Chandan Healthcare Ltd NSE:CHANDAN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chandan Healthcare Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Chandan Healthcare (NSE:CHANDAN) has a Research & Development of ₹0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Chandan Healthcare and its competitors.
Is Chandan Healthcare's Research & Development too high?
Chandan Healthcare's current Research & Development is ₹0 Mil. Overall, Chandan Healthcare has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Chandan Healthcare's Research & Development compare to TMO and DHR?
Chandan Healthcare's Research & Development of ₹0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Chandan Healthcare and its competitors. Chandan Healthcare's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chandan Healthcare stock overvalued right now?
Chandan Healthcare (NSE:CHANDAN) has a current Research & Development of ₹0 Mil. The current Research & Development is ₹0 Mil. Chandan Healthcare's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Chandan Healthcare (NSE:CHANDAN), the current Research & Development is ₹0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chandan Healthcare Business Description

Address Kursi Road, Biotech Park, Sector G, Jankipuram, Lucknow, UP, IND, 226021
Chandan Healthcare Ltd operates laboratories that offer comprehensive pathological investigations. Its services encompass biochemistry, hematology, histopathology, microbiology, and immunology. Additionally, it provide an extensive array of radiology services, including CT scans, X-rays, and MRIs. The company operates single reportable business segment that is Diagnostics Services.
28GF Score

Get the complete analysis for NSE:CHANDAN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹253.00
Price